{"id":62854,"date":"2026-03-27T13:02:23","date_gmt":"2026-03-27T12:02:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/"},"modified":"2026-03-27T13:02:23","modified_gmt":"2026-03-27T12:02:23","slug":"irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/","title":{"rendered":"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors"},"content":{"rendered":"
\n

\nDemands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value<\/i><\/p>\n

\nUnderscores the Company\u2019s Sustained Value Destruction, <\/i>Lack of Permanent Leadership, and Board\u2019s Poor Alignment with Shareholders<\/i><\/p>\n

\nContends Meaningful Board Change \u2013 Including a New Chair \u2013 and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE)–Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (\u201cTeleflex\u201d or the \u201cCompany\u201d) (NYSE: TFX) with 2% ownership, today sent the below letter to the Company\u2019s Board of Directors (the \u201cBoard\u201d) regarding its refusal to engage with potential acquirors, despite receiving interest from multiple credible parties. The letter also urges the Board to immediately take a more constructive and responsible approach to evaluating strategic alternatives.<\/p>\n

\nMarch 27, 2026<\/p>\n

\nTeleflex Incorporated
\n
550 E. Swedesford Road
\n
Suite 400
\n
Wayne, PA 19087<\/p>\n

\nMembers of the Board of Directors:<\/p>\n

\nWe are writing to you on behalf of funds managed by Irenic Capital Management L.P. (together with such funds, \u201cIrenic\u201d or \u201cwe\u201d). Irenic is one of the largest shareholders of Teleflex Incorporated (\u201cTeleflex\u201d or the \u201cCompany\u201d) with 2% ownership.<\/p>\n

\nWe are writing to you following our conversation with Dr. Stephen Klasko, Chairman of the Board of Directors (the \u201cBoard\u201d), last week, during which Dr. Klasko indicated that the Board has directed the Company\u2019s advisors to refuse approaches from potential acquirors of Teleflex. He made clear to us that, in his view, it did not make sense to even have a conversation with interested parties at this point \u2013 regardless of how much such parties might be willing to pay for Teleflex. As we conveyed on the call and in our subsequent private communication with the Board, we firmly believe that posture is unreasonable and irresponsible.<\/span><\/b><\/p>\n

\nOver the past five years, Teleflex has delivered a total shareholder return of negative 73% \u2013 a level of sustained value destruction that demands, at a minimum, openness to evaluating credible opportunities to maximize shareholder value. <\/b>At the same time, the Company is operating without a permanent Chief Executive Officer because the Board failed at its primary job \u2013 properly planning for succession.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Total Shareholder Returns Assuming Dividends are Reinvested in Security<\/b><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Data as of 03\/20\/2026<\/i><\/td>\nTime Period<\/b><\/td>\n<\/tr>\n
<\/td>\n1Y<\/b><\/td>\n3Y<\/b><\/td>\n5Y<\/b><\/td>\n10Y<\/b><\/td>\n<\/tr>\n
Teleflex Incorporated<\/td>\n\n

\n(24 %)<\/p>\n<\/td>\n

\n

\n(54 %)<\/p>\n<\/td>\n

\n

\n(73 %)<\/p>\n<\/td>\n

\n

\n(25 %)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

Benchmark Performance<\/span><\/b><\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

S&P 500<\/td>\n\n

\n16 %<\/p>\n<\/td>\n

\n

\n72 %<\/p>\n<\/td>\n

\n

\n79 %<\/p>\n<\/td>\n

\n

\n276 %<\/p>\n<\/td>\n<\/tr>\n

S&P 500 Healthcare Index<\/td>\n\n

\n1 %<\/p>\n<\/td>\n

\n

\n20 %<\/p>\n<\/td>\n

\n

\n37 %<\/p>\n<\/td>\n

\n

\n159 %<\/p>\n<\/td>\n<\/tr>\n

S&P 500 Healthcare Equipment Index<\/td>\n\n

\n(10 %)<\/p>\n<\/td>\n

\n

\n13 %<\/p>\n<\/td>\n

\n

\n8 %<\/p>\n<\/td>\n

\n

\n164 %<\/p>\n<\/td>\n<\/tr>\n

iShares U.S. Medical Devices ETF<\/td>\n\n

\n(9 %)<\/p>\n<\/td>\n

\n

\n6 %<\/p>\n<\/td>\n

\n

\n3 %<\/p>\n<\/td>\n

\n

\n183 %<\/p>\n<\/td>\n<\/tr>\n

Average of Proxy Peers [1]<\/td>\n\n

\n(2 %)<\/p>\n<\/td>\n

\n

\n(8 %)<\/p>\n<\/td>\n

\n

\n(15 %)<\/p>\n<\/td>\n

\n

\n183 %<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

Teleflex’s Relative Performance vs. Benchmark<\/span><\/b><\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

S&P 500<\/td>\n\n

\n(40 %)<\/p>\n<\/td>\n

\n

\n(126 %)<\/p>\n<\/td>\n

\n

\n(151 %)<\/p>\n<\/td>\n

\n

\n(301 %)<\/p>\n<\/td>\n<\/tr>\n

S&P 500 Healthcare Index<\/td>\n\n

\n(24 %)<\/p>\n<\/td>\n

\n

\n(75 %)<\/p>\n<\/td>\n

\n

\n(110 %)<\/p>\n<\/td>\n

\n

\n(184 %)<\/p>\n<\/td>\n<\/tr>\n

S&P 500 Healthcare Equipment Index<\/td>\n\n

\n(14 %)<\/p>\n<\/td>\n

\n

\n(67 %)<\/p>\n<\/td>\n

\n

\n(81 %)<\/p>\n<\/td>\n

\n

\n(189 %)<\/p>\n<\/td>\n<\/tr>\n

iShares U.S. Medical Devices ETF<\/td>\n\n

\n(15 %)<\/p>\n<\/td>\n

\n

\n(60 %)<\/p>\n<\/td>\n

\n

\n(76 %)<\/p>\n<\/td>\n

\n

\n(208 %)<\/p>\n<\/td>\n<\/tr>\n

Average of Proxy Peers [1]<\/td>\n\n

\n(22 %)<\/p>\n<\/td>\n

\n

\n(46 %)<\/p>\n<\/td>\n

\n

\n(57 %)<\/p>\n<\/td>\n

\n

\n(208 %)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
[1] Executive Compensation Peer Group as per Teleflex’s 2025 Proxy Statement, excluding NuVasive, Inc., which is no longer a standalone publicly listed company.<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Source: Bloomberg<\/i><\/td>\n<\/tr>\n<\/table>\n

\nThe current Board, which is comprised of long-tenured directors, has presided over a sustained period of value destruction. Remarkably, one would think, having decided that the Company is so undervalued that the Board will not even entertain conversations about selling the Company, that members of the Board would be buying stock hand over fist. However, as far as we can tell, Dr. Klasko, in his eighteen years on the Board, has not bought a single share <\/i>(!!) and neither has Candace Duncan nor Neena Patil. In fact, this Board, collectively tenured nearly eighty years, has purchased a grand total of 8,250 shares of Teleflex on the open market. Were the Board collectively a single shareholder, it would be the 223rd largest shareholder on the Bloomberg holders list based on these open market purchases.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Open Market Purchases & Sales by Teleflex Board of Directors<\/b><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Director<\/b><\/td>\nDate Appointed
to Board<\/b><\/td>\n		Days Since
Joining Board<\/b><\/td>\n		Days Since Last Open
Market Purchase<\/b><\/td>\n		Total Shares Purchased
in Open Market<\/b><\/td>\n		Total Shares Sold
in Open Market<\/b><\/td>\n<\/tr>\n
Stephen K. Klasko (Chairman)<\/td>\n\n

\nMay 5, 2008<\/p>\n<\/td>\n

\n

\n6,535<\/p>\n<\/td>\n

\n

\nNo Open Market Purchases<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n

\n

\n14,364<\/p>\n<\/td>\n<\/tr>\n

Stuart A. Randle (Interim CEO)<\/td>\n\n

\nMay 1, 2009<\/p>\n<\/td>\n

\n

\n6,174<\/p>\n<\/td>\n

\n

\n234<\/p>\n<\/td>\n

\n

\n1,000<\/p>\n<\/td>\n

\n

\n24,760<\/p>\n<\/td>\n<\/tr>\n

Candace H. Duncan<\/td>\n\n

\nMay 1, 2015<\/p>\n<\/td>\n

\n

\n3,983<\/p>\n<\/td>\n

\n

\nNo Open Market Purchases<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

Gretchen R. Haggerty<\/td>\n\n

\nSeptember 13, 2016<\/p>\n<\/td>\n

\n

\n3,482<\/p>\n<\/td>\n

\n

\n233<\/p>\n<\/td>\n

\n

\n1,500<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

Andrew A. Krakauer<\/td>\n\n

\nJanuary 1, 2018<\/p>\n<\/td>\n

\n

\n3,007<\/p>\n<\/td>\n

\n

\n234<\/p>\n<\/td>\n

\n

\n3,000<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

John C. Heinmiller<\/td>\n\n

\nJanuary 1, 2019<\/p>\n<\/td>\n

\n

\n2,642<\/p>\n<\/td>\n

\n

\n2,576<\/p>\n<\/td>\n

\n

\n1,250<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

Neena M. Patil<\/td>\n\n

\nApril 29, 2022<\/p>\n<\/td>\n

\n

\n1,428<\/p>\n<\/td>\n

\n

\nNo Open Market Purchases<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

Jaewon Ryu<\/td>\n\n

\nMay 5, 2023<\/p>\n<\/td>\n

\n

\n1,057<\/p>\n<\/td>\n

\n

\n234<\/p>\n<\/td>\n

\n

\n1,500<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
Source: Bloomberg, SEC Filings<\/i><\/td>\n<\/tr>\n<\/table>\n

\nBased on our discussions with other significant shareholders, we believe our concerns are broadly shared. Against this backdrop, it is difficult to understand how the Board can justify refusing to engage with potential buyers. In its response to our communications, the Board asserted that it is making strategic decisions and conducting the search for a permanent CEO that it believes will best position the Company for shareholder value creation. Given its track record of value destruction and lack of alignment, we do not believe this Board has earned the right to unilaterally determine how value is best created on shareholders\u2019 behalf, and particularly not before it has thoroughly assessed all<\/span> potential alternatives.<\/p>\n

\nIn our view, Teleflex requires meaningful change at the Board level \u2013 most notably, a new Chair \u2013 as well as the engagement of independent advisors capable of supporting an objective evaluation of strategic alternatives. We are aware of multiple interested parties, and the Board\u2019s continued unwillingness to engage is not tenable. It is time \u2013 well past time \u2013 for the Board to take a more constructive and responsible approach and begin engaging with credible acquirors.<\/span><\/b><\/p>\n

\nSincerely,<\/p>\n

\nAdam Katz
\n
<\/b>Co-Founder, Chief Investment Officer<\/i><\/p>\n

\nAndy Dodge
\n
<\/b>Co-Founder, Director of Research<\/i><\/p>\n

\nAkshay Amin
\n
<\/b>Managing Director<\/i><\/p>\n

\nAbout Irenic<\/span><\/b><\/p>\n

\nIrenic Capital Management, LP is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Investors:<\/b>
Jeff Shookus
\n
Irenic Capital Management
\n
contact@irenicmgmt.com<\/a><\/p>\n

\nFor Media:<\/b>
Longacre Square Partners
\n
irenic@longacresquare.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company\u2019s Sustained Value Destruction, Lack of Permanent Leadership, and Board\u2019s Poor Alignment with Shareholders Contends Meaningful Board Change \u2013 Including a New Chair \u2013 and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed NEW YORK–(BUSINESS WIRE)–Irenic … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62854","6":"format-standard","7":"category-industry"},"yoast_head":"\nIrenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company\u2019s Sustained Value Destruction, Lack of Permanent Leadership, and Board\u2019s Poor Alignment with Shareholders Contends Meaningful Board Change \u2013 Including a New Chair \u2013 and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed NEW YORK–(BUSINESS WIRE)–Irenic ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T12:02:23+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors\",\"datePublished\":\"2026-03-27T12:02:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/\"},\"wordCount\":956,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/\",\"name\":\"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2026-03-27T12:02:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/","og_locale":"en_US","og_type":"article","og_title":"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors - Pharma Trend","og_description":"Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company\u2019s Sustained Value Destruction, Lack of Permanent Leadership, and Board\u2019s Poor Alignment with Shareholders Contends Meaningful Board Change \u2013 Including a New Chair \u2013 and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed NEW YORK–(BUSINESS WIRE)–Irenic ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-27T12:02:23+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors","datePublished":"2026-03-27T12:02:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/"},"wordCount":956,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/","url":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/","name":"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2026-03-27T12:02:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/irenic-sends-letter-to-teleflex-board-of-directors-regarding-its-refusal-to-engage-with-potential-acquirors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62854"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62854\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}